Şunu aradınız:: genotyping (İngilizce - Maltaca)

genotyping
ġenotipar

the results of any genotyping tests.
(ċ) ir-riżultati ta' kull test għal ġenotip.

initiation of therapy: cyp2d6 genotyping
il-bidu tat-terapija: evalwazzjoni tal-ġenotip ta’ cyp2d6

alternatively, genotyping may also be considered;
inkella, il-ġenotipar għandu jiġi kkunsidrat ukoll.

full genotyping was not performed in all studies.
ma kienx determinat il-ġenotip sħiħ fl-istudji kollha

developing genetic epidemiology tools and standardised genotyping protocols.
l-iżvilupp ta' strumenti għall-epidemjoloġija ġenetika u protokolli standardizzati gall-genotyping.

red blood cell genotyping is not impacted by daratumumab and may be performed at any time.
il-ġenotipar taċ-ċelluli l-ħomor tad-demm mhux affettwat minn daratumumab u jista’ jsir fi kwalunkwe ħin.

tpmt genotyping or phenotyping can be used to identify patients with absent or reduced tpmt activity.
Ġenotipar jew fenotipar ta’ tpmt jistgħu jintużaw biex jidentifikaw pazjenti b’attività nieqsa jew imnaqqsa ta’ tpmt.

alternatively, phenotyping or genotyping may also be considered (see section 4.4).
inkella, finotipar jew ġenotipar jistgħu wkoll jiġu kkonsidrati (ara sezzjoni 4.4).

cyp2c19 and abcb1 genotyping of 10,285 patients in plato provided associations of genotype groups with plato outcomes.
l-għarfien tas-sekwenzi tal-ġeni ta’ cyp2c19 u abcb1 ta’ 10,285 pazjent fi plato wera li hemm rabta bejn il-gruppi ta’ ġenotipi mar-riżultati plato.

from literature, limited data in asian populations are available to assess the clinical implication of genotyping of this cyp on clinical outcome events.
mil-letteratura, id-dejta f’popolazzjonijiet asjatiċi hija limitata biex tiġi evalwata l-implikazzjoni klinika tal-identifikazzjoni tal-ġeni ta’ dan is- cyp fuq kif jirriżultaw l-avvenimenti kliniċi.

the subunit deficiency of patients should be determined prior to treatment by appropriate diagnostic procedures including factor xiii activity and immunoassay and if applicable genotyping.
id-defiċjenza tas-subunità tal-pazjenti għandha tkun magħrufa qabel il-kura permezz ta’ proċeduri dijanjostiċi xierqa li jistgħu jinkludu l-attività tal-fattur xiii u analiżi tal-immunità jew id-determinazzjoni tal-għamla ġenetika.

the congenital factor xiii a-subunit deficiency should be confirmed by appropriate diagnostic procedures including factor xiii activity and immunoassay and if applicable genotyping.
id-defiċjenza konġenitali ta’ subunità a ta’ fattur xiii għandha tiġi kkonfermata permezz ta’ proċeduri dijanjostiċi xierqa li jistgħu jinkludu l-attività tal-fattur xiii u analiżi tal-immunità jew id-determinazzjoni tal-għamla ġenetika.

the contribution for the monitoring of tses concerns the implementation of rapid tests, and for the eradication of scrapie, the destruction of animals found positive and the genotyping of animals.
l-għajnuna għall-monitoraġġ tat-tse tikkonċerna l-implimentazzjoni ta' testijiet mgħaġġla għall-eradikazzjoni ta' l-iscarpie, il-qirda ta' l-annimali li jinstabu pożittivi u l-l-ġenotip ta' l-annimali.

if the patient’s genotype is unknown, an accurate and validated genotyping method should be performed to confirm the presence of the f508del mutation on both alleles of the cftr gene.
jekk il-ġenotip tal-pazjent ma jkunx magħruf, metodu preċiż u vverifikat ta’ ġenotipar għandu jitwettaq biex jikkonferma l- preżenza tal-mutazzjoni f508del fuq iż-żewġ alleli tal-ġene cftr.

for the programmes referred to in articles 29 to 33 costs of analyses are reimbursed up to eur 10 per genotyping test, eur 15 per histopathology test, eur 15 per immuno-histochemistry test and eur 15 per elisa test.
għall-programmi li hemm riferenza għalihom fl-artikoli 29 sa 33 in-nefqa ta’ l-analiżi fil-laboratorju hija mħallsa lura sa eur 10 kull genotyping test, eur 15 kull histopathology test, eur 15 kull immuno-histochemistry test u eur 15 kull test eliza.

patients who are known or suspected to be cyp2c9 poor metabolizers based on genotyping or previous history/ experience with other cyp2c9 substrates should be administered celecoxib with caution, as the risk of dose-dependent adverse effects is increased.
pazjenti magħrufa jew issuspettati li huma metabolizzaturi mhux daqstant tajbin ta ’ cyp2c9 fuq il- bażi tal- ġenotip jew l- istorja/ esperjenza preċedenti b’ substrati oħra ta ’ cyp2c9 għandhom jingħataw celecoxib b’ kawtela, billi dawn għandhom riskju akbar ta ’ effetti ħżiena dipendenti fuq id- doża.

if the cyp2d6 status of the patient has been determined (e.g. by genotyping) or is previously known to be em, ranexa can be used with caution in these patients when they have a combination of several of the above risk factors.
jekk l-istatus cyp2d6 tal-pazjent ikun ġie stabbilit (eż. permezz ta’ ġenotajping) jew huwa diġà magħruf li huwa em, ranexa għandha tintuża bil-kawtela f’dawn il-pazjenti meta jkollhom taħlita ta’ diversi mill-fatturi ta’ riskju ta’ hawn fuq.